10x Genomics’s (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1%

Core Insights - 10x Genomics reported Q3 CY2025 results that exceeded Wall Street's revenue expectations, with sales of $149 million, reflecting a 1.7% year-on-year decline [1][7] - The company provided a positive revenue guidance for Q4 CY2025 at $156 million, which is 3.5% above analyst expectations [1][7] - The GAAP loss per share was $0.22, which was 22.3% better than analysts' consensus estimates of $0.28 [1][7] Company Overview - Founded in 2012, 10x Genomics develops instruments, consumables, and software for analyzing biological systems at single-cell resolution and spatial context [4] Revenue Growth - Over the last five years, 10x Genomics achieved a compounded annual growth rate of 19.6% in sales, outperforming the average healthcare company [5] - However, the company's annualized revenue growth over the last two years was only 4.2%, indicating a slowdown compared to its five-year trend [6] Quarterly Performance - The revenue for Q3 CY2025 was $149 million, surpassing analyst estimates of $142.4 million by 4.6% [7] - The operating margin improved to -21.6%, up from -27.4% in the same quarter last year [7] - The company anticipates a 5.5% year-on-year decline in sales for the next quarter [9] Segment Analysis - The Consumables segment, which represents recurring orders, has shown flat revenue growth over the last two years, lagging behind the overall sales performance of the company [8]